西妥昔单抗联合放化疗治疗局部晚期鼻咽癌患者的临床疗效观察  

Clinical Efficacy of Rituximab Combined with Chemotherapy in the Treatment of Patients with Locally Avanced Nasopharyngeal Carcinoma

作　　者：孙建华[1] 李佳[2] 

机构地区：[1]辽宁省锦州市中心医院,辽宁锦州121000 [2]辽宁医学院附属第一医院,辽宁锦州121000

出　　处：《中国药物经济学》2016年第7期90-92,共3页China Journal of Pharmaceutical Economics

摘　　要：目的探讨西妥昔单抗联合放化疗治疗局部晚期鼻咽癌患者的临床疗效。方法选取2014年6月至2015年12月辽宁省锦州市中心医院收治的100例局部晚期鼻咽癌患者作为研究对象,按照随机数字表法将其分为观察组与对照组,各50例。观察组患者采取西妥昔单抗联合放化疗进行治疗,对照组患者采取临床常规调强适形放射治疗,比较两组患者的治疗效果及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者白细胞减少症发生率明显对照组,口腔黏膜炎、痤疮样皮疹发生率明显高于对照组,差异均有统计学意义(均P<0.05)。结论西妥昔单抗联合放化疗治疗局部晚期鼻咽癌临床疗效确切,不良反应少,具有较高临床应用价值。Objective To investigate the clinical efficacy of the combination of rituximab and chemotherapy in thetreatment of locally advanced nasopharyngeal carcinoma.Methods From June 2014 to December 2015,100 patients with locally advanced nasopharyngeal carcinoma in Jinzhou Central Hospital of Liaoning province were selected as the research object.According to the random number table method,the patients were divided into observation group and control group,each of 50 cases.Patients in the observation group were treated with the combination of chemotherapy and radiotherapy.The patients in the control group were treated with conventional intensity modulated radiation therapy.The treatment effect and adverse reaction were compared between the two groups.Results Observation of patients in the treatment group total efficiency was significantly higher than that of the control group,the difference is statistically significant（P〈0.05）;after treatment observed groups of white blood cells reduce the incidence rate of control group significantly,the incidence of oral mucositis,acne like rash rate was significantly higher than that of the control group,the differences were statistically meter significance（P〈0.05）. Conclusion The clinical efficacy of rituximab combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma is accurate, with less adverse reaction and high clinical application value.

关 键 词：西妥昔单抗 放化疗 局部晚期鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]